Max Dordevic

Max Dordevic has a diverse work experience spanning multiple industries. In 2016, they worked as an Estimator at Lorentz Bruun Construction. In 2018, they were a Researcher at Celling Biosciences, followed by a role as a Researcher at Merck in 2019. In 2020, they served as the Director of Research and International Sales at TRIDENT XI before becoming the Chief Executive Officer at Veritas Innovation later that year. In 2021, Max joined DITEC Ventures as a Principal and became a Chief Executive Officer at NeuroX1 Inc. Additionally, they also became an Editorial Board Member at the Journal of Orthopaedics Study and Sports Medicine in 2021.

Max Dordevic attended The University of Texas at Austin, where they pursued their education. However, no specific information regarding the start year, end year, degree name, or field of study was provided.